Evaluation of Therapeutic Effect of 0.5 mg Colchicine and 5 mg Prednisolone on Oral Aphthae
The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2008 by Mashhad University of Medical Sciences.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
Mashhad University of Medical Sciences
Collaborator:
University of Tehran
Information provided by:
Mashhad University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT00723268
First received: July 24, 2008
Last updated: July 28, 2008
Last verified: July 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether low doses of prednisolone, or colchicine are effective in the treatment of oral aphthae.
| Condition | Intervention | Phase |
|---|---|---|
|
Oral Aphthae |
Drug: Prednisolone Drug: Colchicine |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
| Official Title: | Evaluation of Therapeutic Effect of 0.5 mg Colchicine and 5 mg Prednisolone on Oral Aphthae |
Resource links provided by NLM:
MedlinePlus related topics:
Canker Sores
Drug Information available for:
Prednisolone
Prednisolone acetate
Methylprednisolone acetate
Colchicine
Methylprednisolone
Prednisolone sodium phosphate
Prednisolone phosphate
Prednisolone sodium succinate
Methylprednisolone sodium succinate
U.S. FDA Resources
Further study details as provided by Mashhad University of Medical Sciences:
Primary Outcome Measures:
- frequency of ulcers [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 30 |
| Study Start Date: | May 2007 |
| Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Prednisolone |
Drug: Prednisolone
5MG Prednisolone per day for 3 months
|
| Active Comparator: Colchicine |
Drug: Colchicine
0.5 MG Colchicine per day for 3 months
|
Detailed Description:
Treatment of recurrent aphthous stomatitis (RAS) remains, to date, empirical and non-specific. The main goals of therapy are to minimize pain and functional disabilities as well as decrease inflammatory reactions and frequency of recurrences.
Eligibility| Ages Eligible for Study: | 15 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Confirmation of clinical diagnosis of aphthae
- Having the experience of oral aphthae at least once in a month
- Two weeks wash out periods after the last treatment
Exclusion Criteria:
- History of any systemic disease
- Using drugs which affect immune system
- Pregnancy and breast feeding
- Aphthous related syndromes
Contacts and Locations
More Information
Additional Information:
No publications provided
| Responsible Party: | Mashhad University of Medical Science, Mashhad Dental Research Center |
| ClinicalTrials.gov Identifier: | NCT00723268 History of Changes |
| Other Study ID Numbers: | 286293, 286293 |
| Study First Received: | July 24, 2008 |
| Last Updated: | July 28, 2008 |
| Health Authority: | Iran: Ethics Committee |
Keywords provided by Mashhad University of Medical Sciences:
|
Oral ulcers |
Additional relevant MeSH terms:
|
Stomatitis, Aphthous Stomatitis Mouth Diseases Stomatognathic Diseases Colchicine Methylprednisolone acetate Prednisolone acetate Prednisolone Methylprednisolone Methylprednisolone Hemisuccinate Prednisolone hemisuccinate Prednisolone phosphate Tubulin Modulators Antimitotic Agents Mitosis Modulators |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Gout Suppressants Antirheumatic Agents Therapeutic Uses Antineoplastic Agents Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antiemetics Autonomic Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on June 17, 2013